Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Rui Zou 1 Article
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
Rui Zou, Xiao Zhou, Hailing Liu, Peng Wang, Fan Xia, Liqing Kang, Lei Yu, Depei Wu, Zhengming Jin, Changju Qu
Cancer Res Treat. 2023;55(4):1363-1368.   Published online June 14, 2023
DOI: https://doi.org/10.4143/crt.2023.371
AbstractAbstract PDFPubReaderePub
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin’s lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton’s tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.

Citations

Citations to this article as recorded by  
  • Are we ready for personalizedCAR‐Ttherapy?
    Anna Strzelec, Grzegorz Helbig
    European Journal of Haematology.2024; 112(2): 174.     CrossRef
  • Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
    Ying Zhang, Hongzhi Geng, Liangyu Zeng, Jiaqi Li, Qin Yang, Sixun Jia, Xiangping Zong, Wenzhi Cai, Shuangzhu Liu, Yutong Lu, Lei Yu, Caixia Li, Depei Wu
    Hematological Oncology.2024;[Epub]     CrossRef
  • Therapeutic targeting of DNA methylation alterations in cancer
    Abigail V. Lee, Kevin A. Nestler, Katherine B. Chiappinelli
    Pharmacology & Therapeutics.2024; 258: 108640.     CrossRef
  • Cytarabine/methotrexate/rituximab

    Reactions Weekly.2024; 2003(1): 302.     CrossRef
  • A systematic review of primary central nervous system lymphoma
    Lei Zhang, Qingyuan Zhang
    Holistic Integrative Oncology.2024;[Epub]     CrossRef
  • The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review
    Bibhu Prasad Satapathy, Pooja Sheoran, Rohit Yadav, Dewan Chettri, Dhruba Sonowal, Chinmayee Priyadarsini Dash, Prachi Dhaka, Vivek Uttam, Ritu Yadav, Manju Jain, Aklank Jain
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Siglecs-mediated immune regulation in neurological disorders
    Huifang Tu, Limei Yuan, Bo Ni, Yufeng Lin, Kaiyuan Wang
    Pharmacological Research.2024; 210: 107531.     CrossRef
  • 3,626 View
  • 249 Download
  • 4 Web of Science
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP